1. Home
  2. TBN vs ADCT Comparison

TBN vs ADCT Comparison

Compare TBN & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBN
  • ADCT
  • Stock Information
  • Founded
  • TBN 2009
  • ADCT 2011
  • Country
  • TBN Australia
  • ADCT Switzerland
  • Employees
  • TBN 39
  • ADCT N/A
  • Industry
  • TBN
  • ADCT Biotechnology: Pharmaceutical Preparations
  • Sector
  • TBN
  • ADCT Health Care
  • Exchange
  • TBN NYSE
  • ADCT Nasdaq
  • Market Cap
  • TBN 239.3M
  • ADCT 224.3M
  • IPO Year
  • TBN 2024
  • ADCT 2020
  • Fundamental
  • Price
  • TBN $16.79
  • ADCT $2.03
  • Analyst Decision
  • TBN Buy
  • ADCT Strong Buy
  • Analyst Count
  • TBN 3
  • ADCT 5
  • Target Price
  • TBN $34.67
  • ADCT $8.00
  • AVG Volume (30 Days)
  • TBN 12.9K
  • ADCT 1.6M
  • Earning Date
  • TBN 01-11-2025
  • ADCT 11-07-2024
  • Dividend Yield
  • TBN N/A
  • ADCT N/A
  • EPS Growth
  • TBN N/A
  • ADCT N/A
  • EPS
  • TBN N/A
  • ADCT N/A
  • Revenue
  • TBN N/A
  • ADCT $70,717,000.00
  • Revenue This Year
  • TBN N/A
  • ADCT $6.58
  • Revenue Next Year
  • TBN N/A
  • ADCT $11.78
  • P/E Ratio
  • TBN N/A
  • ADCT N/A
  • Revenue Growth
  • TBN N/A
  • ADCT N/A
  • 52 Week Low
  • TBN $15.75
  • ADCT $1.18
  • 52 Week High
  • TBN $25.99
  • ADCT $6.04
  • Technical
  • Relative Strength Index (RSI)
  • TBN N/A
  • ADCT 45.58
  • Support Level
  • TBN N/A
  • ADCT $1.80
  • Resistance Level
  • TBN N/A
  • ADCT $3.49
  • Average True Range (ATR)
  • TBN 0.00
  • ADCT 0.40
  • MACD
  • TBN 0.00
  • ADCT -0.02
  • Stochastic Oscillator
  • TBN 0.00
  • ADCT 21.01

About TBN TAMBORAN RESOURCES CORPORATION

Tamboran Resources Corp is a gas company focused on supporting the Net Zero CO2 energy transition in Australia and Asia-Pacific through developing low CO2 unconventional gas resources in the Australian Northern Territory.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.

Share on Social Networks: